Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

APHA awarded $100,000 to develop brucellosis vaccine
Wholesale vaccination of livestock can be a cost-effective way of controlling brucellosis.
Vaccine to deliver lasting benefits to human and animal health

The Animal and Plant Health Agency (APHA) has been awarded $100,000 in the AgResults’ Brucellosis Vaccine Prize competition. The money will be used to develop a vaccine that is effective for use against small ruminants across the developing world.

The APHA received the funding for Phase 1 of the vaccine development and was awarded based on the agency's scientific soundness, suitable research and appropriate manufacturing capabilities.

Dr John McGiven, who is leading the project, said: “We feel the AgResults competition elevates recognition of the significance of this insidious and debilitating disease. For many years we have been focusing on improved methods for the serodiagnosis of brucellosis and this research revealed to us a route towards a new type of vaccine against brucellosis.

“This competition gave us additional incentive to pull these innovative concepts together in the belief that we can make a big difference to brucellosis control.”

Brucellosis is a devastating disease that leads to infertility, abortions and decreased milk production. It affects many animals, including small ruminants and is endemic in a number of developing countries.

Wholesale vaccination of livestock can be a cost-effective way of controlling the disease and reducing its impact on human and animal health. However, existing vaccines are unsafe for use in pregnant animals, have variable efficacy, and can harm humans.

The Brucellosis Vaccine Prize Competition, managed by AgResults, has three phases and may run for 10 years. $30 million is available to entrants, with three milestone payments at different stages.

Dr McGiven’s team is now working on Phase 2 of the vaccine development, by developing a proof of concept vaccine that meets efficacy and safety requirements. It is hoped the vaccine will deliver lasting benefits to human and animal health.

Become a member or log in to add this story to your CPD history

Survey launched to investigate EHV

News Story 1
 Zoetis has launched a new survey to identify management techniques for Equine Herpes Virus (EHV).

EHV is a contagious, airborne virus that can cause respiratory problems and severe diseases in horses and ponies. It spreads among horses over short distances, direct contact and through shared equipment.

The survey will explore current knowledge and management practices with EHV in the UK. It is quick to complete and participants could win one of 10 equine first aid kits.

Complete the survey here

Click here for more...
News Shorts
WSAVA launches pet travel guidance factsheet

A new pet travel guidance factsheet for veterinary professionals and caregivers has been developed by the WSAVA in collaboration with the World Veterinary Association.

The Dog and Cat Welfare During Transport factsheet provides step-by-step guidance for all stages of a journey, from pre-travel checklists to post-travel care.

Brachycephalic breeds or animals prone to travel-related anxiety are given special focus in this guide, which also provides links to IATA container regulation and WSAVA vaccination guidelines.